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A B S T R A C T
Background: Our goal was to perform a systematic review of the literature on the use of intravenous
magnesium sulfate (MgSO4) for non-eclamptic status epilepticus (SE) and refractory status epilepticus
(RSE).
Methods: Articles from MEDLINE, BIOSIS, EMBASE, Global Health, Scopus, Cochrane Library, the
International Clinical Trials Registry Platform, clinicaltrials.gov (inception to June 2015), reference lists
of relevant articles, and gray literature were searched. The strength of evidence was adjudicated using
both the Oxford and GRADE methodology by two independent reviewers.
Results: We identiﬁed 19 original articles. A total of 28 patients were described in these articles with
11 being adult, 9 being pediatric, and 8 of unknown age. Seizure reduction/control with IV MgSO4
occurred in 14 of the 28 patients (50.0%), with 2 (7.1%) and 12 (42.9%) displaying partial and complete
responses respectively. Seizures recurred upon withdrawal of MgSO4 therapy in 50% of the patients
whom had reduction/control of their SE/RSE. Three patients had recorded adverse events related to
MgSO4 therapy.
Conclusions: Oxford level 4, GRADE D evidence exists to suggest a trend towards improved seizure
control with the use of intravenous MgSO4 for non-eclamptic RSE. Routine use of IV MgSO4 in non-
eclamptic SE/RSE cannot be recommended at this time. Further prospective study of this drug is required
in order to determine its efﬁcacy as an anti-epileptic in this setting.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Magnesium sulfate (MgSO4) is a drug that has garnered some
interest within the epilepsy community [1]. Whether administered
orally, or intravenous (IV), MgSO4 has displayed some efﬁcacy in
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is not well understood, it is believe to derive its anti-epileptic
properties from N-methyl D-aspartate (NMDA) receptor inhibition.
To date, a few animal models support this concept [3–6].
Clinically, MgSO4 has seen much attention within the obstetrics
literature as an effective prophylactic and therapeutic agent for
pre-eclampsia and eclampsia, respectively [7]. Furthermore, the
lack of signiﬁcant side effects is appealing due to concerns about
fetal toxicity. The efﬁcacy of MgSO4 as an AED in the setting of
eclampsia is well documented since the early 1900s, with the
mechanism of action attributed to both NMDA receptor antago-
nism and cerebral vasodilation. In addition, systematic reviews
have demonstrated the superiority of MgSO4 over diazepam,
phenytoin and lytic cocktails in the setting of eclampsia [8–10].
During status epilepticus (SE) and refractory status epilepticus
(RSE) the NMDA receptor plays a key role in pharmaco-resistance
and epileptigenicity. As seizures remain uncontrolled, there is an
up-regulation of the NMDA receptor, leading to a glutamate
mediated excitotoxicity and seizure potentiation [11,12]. This has
lead to the interest in NMDA receptor antagonists as AED in theserved.
F.A. Zeiler et al. / Seizure 32 (2015) 100–108 101setting of SE/RSE. Ketamine is an example of one such drug which
has displayed some efﬁcacy in this setting [13].
The use of MgSO4 in the setting of non-eclamptic SE/RSE has
been mentioned in protocols and reviews of therapies [14–16]. To
date however there are only a small number of cases describing the
use of IV MgSO4 for non-eclamptic SE/RSE [17–37].
Our goal was to perform a systematic review of the literature on
the use of IV MgSO4, a NMDA receptor antagonist, for non-
eclamptic SE/RSE.
2. Materials and methods
A systematic review using the methodology outlined in the
Cochrane Handbook for Systematic Reviewers [39] was conducted.
The data was reported following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [40]. The review
questions and search strategy were decided upon by the primary
author and supervisor.
2.1. Search question, population, inclusion and exclusion criteria
The question posed for systematic review was: What is the
effectiveness of IV MgSO4 for non-eclamptic SE/RSE? The deﬁnition
of SE and RSE was as per the Neurocritical Care Society guidelines
on the management of SE [41]. The deﬁnition for RSE was as
follows: any patient(s) whom continue to experience either clinical
or electro-graphic seizures after receiving adequate doses of an
initial benzodiazepine followed by a second acceptable antiepi-
leptic drug (AED) will be considered refractory [41]. Non-eclamptic
SE was deﬁned as SE in the absence of pregnancy, or SE in the
setting of pregnancy but in the absence of the other features of
eclampsia such as hypertension and multi-organ dysfunction. The
term generalized refractory status epilepticus (GRSE) was used to
refer to generalized tonic-clonic RSE. The term focal refractory
status epilepticus (FRSE) was used to refer focal tonic-clonic RSE.
The term multi-focal refractory status epilepticus (MFRSE) was
used to refer to RSE that had a mutli-focal tonic-clonic nature. The
term non-convulsive refractory status epilepticus (NCRSE) was
used for non-convulsive seizures that fulﬁlled the criteria for RSE.
All studies, prospective and retrospective of any size based on
human subjects were included. The reason for an all-inclusive
search was based on the small number of studies of any type
identiﬁed by the primary author during a preliminary search of
MEDLINE.
The primary outcome measure was electrographic seizure
control, deﬁned as: complete resolution, partial seizure reduction,
and failure. This qualitative seizure response grading was used
given the lack of detail around the electroencephalographic
response reported within the studies found. Secondary outcome
measures were patient outcome (if reported), and adverse effects
of the administration of MgSO4.
Inclusion criteria were: All studies including human subjects
whether prospective or retrospective, all study sizes, any age
category, the documented use of IV MgSO4 for the purpose of
seizure control in the setting of SE/RSE, and the absence of pre-
eclampsia/eclampsia as the cause of neurological deterioration or
seizures. Exclusion criteria were: animal and non-English studies,
treatment with oral MgSO4, and any studies describing patients
with pre-eclampsia/eclampsia.
2.2. Search strategy
MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS, and
Cochrane Library from inception to June 2015 were searched
using individualized search strategies for each database. The
search strategy for MEDLINE can be seen in Appendix A of thesupplementary material, with a similar search strategy utilized for
the other databases. In addition, the World Health Organizations
International Clinical Trials Registry Platform and ClinicalTrials.-
gov were searched looking for studies planned or underway, with
none identiﬁed.
As well, meeting proceedings for the last 10 years looking for
ongoing and unpublished work based on MgSO4 for SE/RSE were
examined. The meeting proceedings of the following professional
societies were searched: Canadian Neurological Sciences Federation
(CNSF), American Association of Neurological Surgeons (AANS),
Congress of Neurological Surgeons (CNS), European Neurosurgical
Society (ENSS), World Federation of Neurological Surgeons (WFNS),
American Neurology Association (ANA), American Academy of
Neurology (AAN), European Federation of Neurological Science
(EFNS), World Congress of Neurology (WCN), Society of Critical Care
Medicine (SCCM), Neurocritical Care Society (NCS), World Federa-
tion of Societies of Intensive and Critical Care Medicine (WFSICCM),
American Society for Anesthesiologists (ASA), World Federation of
Societies of Anesthesiologist (WFSA), Australian Society of Anesthe-
siologists, International Anesthesia Research Society (IARS), Society
of Neurosurgical Anesthesiology and Critical Care (SNACC), Society
for Neuroscience in Anesthesiology and Critical Care, and the
Japanese Society of Neuroanesthesia and Critical Care (JSNCC).
Finally, reference lists of any review articles or systematic
reviews on seizure management were reviewed for relevant
studies on MgSO4 usage for SE/RSE that were missed during the
database and meeting proceeding search.
2.3. Study selection
Utilizing two reviewers (FZ and MM), a two-step review of all
articles returned by our search strategies was performed. First, the
reviewers independently screened all titles and abstracts of the
returned articles to decide if they met the inclusion criteria.
Second, full text of the chosen articles was then assessed to conﬁrm
if they met the inclusion criteria and that the primary outcome of
seizure control was reported in the study. Any discrepancies
between the two reviewers were resolved by a third party (CK).
2.4. Data collection
Data was extracted from the selected articles and stored in an
electronic database. Data ﬁelds included: patient demographics,
type of study (prospective or retrospective), number of patients,
dose of MgSO4 used, timing to administration of MgSO4, duration
of MgSO4 administration, time to effect of drug, how many other
AED were utilized prior to implementation of MgSO4, degree of
seizure control (as described previously), adverse effects, and
patient outcome.
2.5. Quality of evidence assessment
Assessment of the level of evidence for each included study was
conducted by a panel of two independent reviewers, utilizing the
Oxford criteria [42] and the Grading of Recommendation Assess-
ment Development and Education (GRADE) criteria [43–48] for
level of evidence. We elected on utilizing two different systems to
grade level of evidence given that these two systems are amongst
the most commonly used. We believe this would allow a larger
audience to follow our systematic approach in the setting of
unfamiliarity with a particular grading system.
The Oxford criteria consist of a 5 level grading system for
literature. Level 1 is split into subcategories 1a, 1b, and 1c which
represent a systematic review of randomized control trials (RCT)
with homogeneity, individual RCT with narrow conﬁdence
interval, and all or none studies respectively. Oxford level 2 is
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studies with homogeneity of data, individual cohort study or low
quality RCT, and outcomes research respectively. Oxford level 3 is
split into 3a and 3b representing systematic review of case-control
studies with homogeneity of data and individual case-control
study respectively. Oxford level 4 represents case-series and poor
cohort studies. Finally, Oxford level 5 represents expert opinion.
The GRADE level of evidence is split into 4 levels: A, B, C and D.
GRADE level A represents high evidence with multiple high quality
studies having consistent results. GRADE level B represents
moderate evidence with one high quality study, or multiple low
quality studies. GRADE level C evidence represents low evidence
with one or more studies with severe limitations. Finally, GRADE
level D represents very low evidence based on either expert
opinion or few studies with severe limitations.
Any discrepancies between the grading of the two reviewers (FZ
and MM) were resolved via a third party (CK).
2.6. Statistical analysis
A meta-analysis was not performed in this study due to the
heterogeneity of data within the articles and the presence of a
small number of low quality retrospective studies.
3. Results
The results of the search strategy across all databases and other
sources are summarized in Fig. 1. Overall a total of 809 articlesFig. 1. Flow diagram were identiﬁed, with 800 from the database search and 9 from the
search of published meeting proceedings. After removing dupli-
cates, there were 599 articles. By applying the inclusion/exclusion
criteria to the title and abstract, we identiﬁed 47 articles that ﬁt
these criteria with 38 from the database search and 9 were from
published meeting proceedings. Applying the inclusion/exclusion
criteria to the full text documents, only 19 articles were eligible for
inclusion in the systematic review, with 10 from database and
9 from meeting proceeding sources. The articles that were
excluded were done so because they either did not report details
around the administration of IV MgSO4 for seizure control, or
because they were review articles. Reference sections from these
review articles were searched for any other articles missed in the
database search, with 3 being identiﬁed. These were subsequently
added to the ﬁnal group of included articles to make a total of
22 articles for the ﬁnal review.
Of the 22 articles included in the review [17–38], 19 were
original studies [17–35] and 3 were companion publications [36–
38] with duplicate patient data. Madisi et al. [36] and Madisi et al.
[37] were meeting proceedings describing the same patient that
was eventually described and updated meeting proceeding
Berkeley et al. [18]. Similarly, Sahin et al. [38] contained duplicate
patient data from 1 of the 2 patients described in Sahin et al.
[28]. These three articles [36–38] were not included in the ﬁnal
data summary in order to prevent duplication of patient data.
However, Sahin et al. [38] provided some longer term follow up
data on one patient in Sahin et al. [28], which was included in the
outcome data section.of search results.
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3 retrospective case series [28,31,35] and 16 retrospective case
reports [17–27,29,30,32–34]. All were single center reports. Eleven
articles described the use of MgSO4 in adults [18,21,23–
26,29,30,32,34,35]. Eight studies described pediatric patients
[17,19,20,22,27,28,33,35]. One study described an adult and
pediatric patient [35]. Finally, one study failed to document the
age of the patient’s treated [31].
Across all studies, a total of 28 patients were documented as
having IV MgSO4 administered for SE or RSE (mean 1.5 patients/
study; range: 1–8 patients/study). Nine patients were pediatric
with a mean age of 11.4 years (age range: 2–17 years). Eleven
patients were adult with a mean age of 27.5 years (age range: 18–
57 years). Eight patients had no documented age [31].
Seizures were classiﬁed as GSE in 1 patient [27], GRSE in
13 patients [17,18,20–23,25,26,28,32,34,35], FRSE in 2 patients
[19,29], MFRSE in 2 patients [28,33], NCRSE in 1 patient [30], and non
deﬁned SE/RSE in 9 patients [24,31].
The etiology of SE/RSE varied signiﬁcantly and were as follows:
fever induced refractory epilepsy syndrome (FIRES)/New onset
resistant status epilepticus (NORSE) in 3 patients [18,23,33],
autoimmune encephalitis in 2 patients [19,24], known pre-existing
epilepsy in 3 patients [20,22,32], encephalitis in 3 patients [22,28],
acute intermittent porphyria (AIP) in 1 patient [27], POLG1 mutation
with associated epilepsy in 3 patients [29,35], paraneoplastic related
in 1 patient [30], vitamin B6 deﬁciency in 1 patient [34], and
unknown in 11 patients [17,25,26,31].
Study demographics and patient characteristics for all studies
can be seen in Table 1, while treatment characteristics and seizure
outcome are reported in Table 2.
3.1. MgSO4 treatment characteristics
Only 7 of the 19 original articles provided [21,25,27,31,33–35]
details around the treatment parameters for IV MgSO4. The
remaining 12 studies only referred to the use of MgSO4 in the
management of SE/RSE, without providing any information on
dosing [17–20,22–24,26,28–30,32].
Four studies [21,27,33,34] described an IV loading dose ranging
from 3 to 6 g, followed by a continuous infusion ranging from
0.75 g/h up to 6 g/h. The duration of treatment for these studies
varied from 2 to 7 days.
One study described only a continuous infusion of 1 g/h for a 5 day
duration [25]. Another study described intermittent bolus dosing of
10 mL of 25% MgSO4 solution, up to three times [31]. Finally, one
study described targeting a serum magnesium concentration of
3.5 mmol/L via an undisclosed MgSO4 dosing schedule [35].
Duration of treatment prior to implementation of MgSO4
therapy was documented in 10 articles [19,21–23,25,27,30,
32,33,35], ranging from 3 to 35 days (mean = 19.2 days; medi-
an = 19). The remaining 9 articles failed to mention the duration of
therapy prior to implementation of MgSO4. The number of AEDs
administered prior to MgSO4 therapy was documented in
17 studies [17–29,32–35], with the total number ranging from
1 to 14 (mean = 7.7, median = 8). Similarly, the duration of MgSO4
treatment was described in 9 of the 19 studies, with treatment
duration ranging from 0.33 h to 7 days (median = 4 days,
mean = 4.0 days). Treatment characteristics for the adult studies
can be seen in Table 2.
3.2. Seizure response
Seizure response to IV MgSO4 occurred in 14 of the 28 patients
(50.0%) included in the review, with 2 patients [21,35] (7.1%)
displaying partial EEG based response and 12 patients
[24,27,31,33,35] (42.9%) displaying complete resolution of seizures.Fourteen of the 28 patients (50.0%) had no response to MgSO4
therapy [17–20,22,23,25,26,28–30,32,34].
Looking at seizure subtype: 3 of the 13 (23.1%) GRSE patients
responded, 1 of the 2 (50.0%) MFRSE patients responded, the 1 GSE
patient responded, and all 9 (100%) of the ‘‘unknown’’ SE/RSE
patients responded to IV MgSO4 therapy. None of the FRSE or
NCRSE patients responded to MgSO4 therapy.
Seizure recurrence upon withdrawal of IV MgSO4 therapy
occurred in 7 of the 14 (50.0%) of those patients whom initially
responded.
3.3. Adverse effects of MgSO4
Adverse events related to IV MgSO4 therapy were documented
in 3 patient across 3 studies [21,27,32]. One patient developed limb
weakness [27]. Two patients developed heart block related to high
dose IV MgSO4 dosing [21,32]. No cardiac arrest or respiratory
complications were reported.
The remaining 16 studies did not document adverse events.
3.4. Outcome
Outcome data was poorly recorded in the majority of the
studies included within the review. Data on patient outcome was
available in only 11 of the 28 (39.3%) of the patients treated
[17,21,24,25,28,29,35]. Modiﬁed Rankin scores (mRS) were ap-
proximated based on the available data within the reports, with
mRS scores of 1, 2, 3, 4, 5, or 6 recorded in 2 (18.2%), 2 (18.2%), 0
(0%), 2 (18.2%), 1 (9.1%), and 4 (36.4%), respectively.
No identiﬁable trend in outcomes could be seen based on
seizure subtype, etiology of seizure, or comparing MgSO4
responders to non-responders.
3.5. Level of evidence for MgSO4
Based on the 19 original articles included in the ﬁnal review, all
fulﬁll Oxford level 4, GRADE D evidence to suggest some potential
impact of IV MgSO4 on seizure control in the setting of non-
eclamptic RSE. The role of IV MgSO4 in the management of non-
eclamptic SE is unclear.
Summary of the level of evidence can be seen in Table 3.
4. Discussion
Given the limited literature to date utilizing IV MgSO4 therapy
in the management of SE/RSE, we decided to perform an extensive
systemic review of the literature in order to determine its impact in
the setting of non-eclamptic SE/RSE. Through our review we
identiﬁed 19 original articles [17–35]. A total of 28 patients were
described in these articles with 11 being adult, 9 being pediatric,
and 8 of unknown age. All studies were retrospective case reports/
series. Seizure reduction/control with IV MgSO4 occurred in 14 of
the 28 patients (50.0%), with 2 (7.1%) and 12 (42.9%) displaying
partial and complete responses respectively. Seizures recurred
upon withdrawal of MgSO4 therapy in 50% of the patients whom
had reduction/control of their SE/RSE. Three patients had recorded
adverse events related to MgSO4 therapy. Patient outcome data
was too sparingly documented for any strong conclusion, with no
identiﬁable trend in outcomes for the responders versus the non-
responders. All studies were an Oxford level 4, GRADE D level of
evidence. Thus, based on this review, we can currently provide
Oxford level 4, GRADE D recommendations that IV MgSO4 may
provide some impact on seizure control in the setting of non-
eclamptic SE/RSE.
A few important points can be seen within our review. First, IV
MgSO4 appears moderately effective at impacting seizure control
Table 1
Study characteristics and patient demographics.
Reference Number
of patients
treated
with MgSO4
Study type/
design
Article location Mean age
(years)
Etiology of seizures/type of
SE
Mean#
Meds
Prior to
MgSO4
Mean time
until MgSO4
administration
(days)
Baxter et al. [17] 1 Retrospective
Case Report
Journal Manuscript 6.8 Etiology: Unknown
Type: GRSE
14 Unknown
Berkeley et al. [18] 1 Retrospective
Case Report
Meeting Abstract 23 Etiology: FIRES/NORSE
Type: GRSE
11 Unknown
Broomall et al. [19] 1 Retrospective
Case Report
Journal Manuscript 11 Etiology: Autoimmune
Encephalitis, Anti-Gad
Type: FRSE/NCRSE
12 19
Dionisio et al. [20] 1 Retrospective
Case Report
Journal Manuscript 17 Etiology: Juvenile
Myoclonic Epilepsy
Type: GRSE
7 Unknown
Fisher et al. [21] 1 Retrospective
Case Report
Journal Manuscript 22 Etiology: Known Epilepsy
and CP
Type: GRSE
5 14
Gedik et al. [22] 1 Retrospective
Case Report
Journal Manuscript 5 Etiology:
Meningoencephalitis
Type: GRSE
10 11
Nandakumar et al. [23] 1 Retrospective
Case Report
Meeting Abstract 24 Etiology: NORSE
Type: GRSE
9 19
Neligan et al. [24] 1 Retrospective
Case Report
Meeting Abstract 33 Etiology: NMDA Receptor
Encephalitis
Type: Unknown SE/RSE
6 Unknown
Pandey et al. [25] 1 Retrospective
Case Report
Journal Manuscript 18 Etiology: Unknown
Type: GRSE
6 35
Robakis et al. [26] 1 Retrospective
Case Report
Journal Manuscript 30 Etiology: Unknown
Type: GRSE
8 Unknown
Sadeh et al. [27] 1 Retrospective
Case Report
Meeting Abstract 16 Etiology: AIP
Type: GSE
1 3
Sahin et al. [28]** 2 Retrospective
Case Series
Journal Manuscript 13 and 15 1 ! Etiology: Presumed
Encephalitis
Type: MFRSE
2 ! Etiology: Presumed
Encephalitis
Type: GRSE
4 Unknown
Savard et al. [29] 1 Retrospective
Case Report
Meeting Abstract 27 Etiology: POLG1 Epilepsy
Type: FRSE
8 Unknown
Shin et al. [30] 1 Retrospective
Case Report
Meeting Abstract 57 Etiology: Paraneoplastic
from clear cell ovarian
cancer
Type: NCRSE
Unknown 14
Storchheim et al. [31] 8 Retrospective
Case Series
Journal Manuscript Unknown Etiology: Unknown
Type: Unknown SE/RSE
Unknown Unknown
Strzelczyk et al. [32] 1 Retrospective
Case Report
Journal Manuscript 21 Etiology: Known Epilepsy
Type: GRSE
10 15
Tan et al. [33] 1 Retrospective
Case Report
Meeting Abstract 2 Etiology: FIRES
Type: MFRSE
10 35
Val-Morales et al. [34] 1 Retrospective
Case Report
Journal Manuscript 29 Etiology: Vitamin B6
Deﬁciency
Type: GRSE
5 Unknown
Visser et al. [35] 2 Retrospective
Case Series
Journal Manuscript 19 and 17 1 ! Etiology: POLG1
Epilepsy
Type: GRSE
2 ! Etiology: POLG1
Epilepsy
Type: GRSE
5 27
Madisi et al. [36]* 1 Retrospective
Case Report
Meeting Abstract 23 Etiology: FIRES/NORSE
Type: GRSE
Unknown Unknown
Madisi et al. [37]* 1 Retrospective
Case Report
Meeting Abstract 23 Etiology: FIRES/NORSE
Type: GRSE
Unknown Unknown
Sahin et al. [38]** 1 Retrospective
Case Report
Journal Manuscript 15 Etiology: Presumed
Encephalitis
Type: GRSE
3 Unknown
AED, anti-epileptic drug; IV, intravenous; TBI, traumatic brain injury; SE, status epilepticus; RSE, refractory status epilepticus; GSE, generalized status epilepticus; GRSE,
generalized refractory status epilepticus; FRSE, focal refractory status epilepticus; MFRSE, multi-focal refractory status epilepticus; NCRSE, non-convulsive refractory status
epilepticus; FIRES, fever induced refractory epilepsy syndrome; NORSE, new onset resistant status epilepticus; NMDA, n-methyl d-aspartate; CP, cerebral palsy; hrs, hours.
* Berkley et al. [18], Madisi et al. [36], and Madisi et al. [37] all contain the same patient data. The data from Berkely et al. [18] was the only data included in the ﬁnal
analysis.
** Sahin et al. [28,38] report the same patient. The data for this patient was synthesized from both reports, but not duplicated.
* Duplicate patient.
** Patient 2 in Sahin 2001 is a duplicate.
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Table 2
MgSO4 Treatment Characteristics, Seizure Response, and Outcome.
Reference Number
of Patients
Treated
with MgSO4
MgSO4 dose Mean Duration
of MgSO4
Administration
(days)
Other AED On
Board at Time of
MgSO4
Administration
Electrographic
Seizure Response
Recurrence
after
Withdrawal
of MgSO4
Adverse Effects
to MgSO4
Patient Outcome
Baxter et al. [17] 1 NA NA NA Ineffective NA NA Intractable multi-focal
seizures, nasogastric feed and
hypertonic quadriplegic
Berkeley et al. [18] 1 NA NA Unclear Ineffective NA NA No effect from Mg. RSE was
treated with
PLEX+ rituximab
Broomall et al. [19] 1 NA 4 Felbamate
Ketamine
Phenobarbital
Midazolam
Topiramate
Pentobarbital
Other Therapies:
IVIG
Rituximab
Ineffective (seizures
continued upon
weaning of
pentobarbital)
NA NA SE was stopped with
allopregnanolone.
Dionisio et al. [20] 1 NA NA NA Ineffective NA NA Continued having ongoing
seizures until treated with
IVIG
Fisher et al. [21] 1 Load=4g
Maintenance =
2,3,5,6 g/hR
(increasing
doses over time)
2 Pentobarbital
Phenobarbital
Phenytoin
Carbamazepine
Valproic acid
Blunting of spike
activity (‘‘not likely’’
to be signiﬁcant or
a cause of the Mg)
Yes Hypotension,
1st degree heart
block,
Peripheral
neuromuscular
blockage
Died 10d post MgSO4
withdrawal
Gedik et al. [22] 1 NA 4 Levetiracetam
Diphenylhydantoin
ineffective NA NA No change mentioned
Nandakumar
et al. [23]
1 NA NA Levetiracetam
Phenobarbital
Phenytoin
Propofol
Alfentanil
Midazolam
Ineffective NA NA Died 4 days post MgSO4
Neligan et al. [24] 1 NA NA Unclear AED On board
Other Therapies:
Rituximab
Plasma exchange
Seizure cessation No NA Slowly recovering, still an
inpatient 4 months later
Pandey et al. [25] 1 1g/hr 5 Thiopentone
Midazolam
Phenytoin
Phenobarbitone
Lamotrigine
Clonazepam
Ineffective N/A NA Good neurologic recovery
with some retrograde
amnesia
Robakis et al. [26] 1 NA 7 Midazolam
Pentobarbital
Phenobarbital
No noticeable change NA NA Remained in RSE for
5 months
Sadeh et al. [27] 1 Load = 3g
Maintenance =1,
0.75g/hr
7 Phenytoin Seizure cessation Yes Pronounced
weakness of upper
limbs
Seizures ceased, neurological
state improved but still
signiﬁcantly impaired
Sahin et al. [28]** 2 NA NA 1!pentobarbital
Phenobarbital
Midazolam
Propfol
2!pentobarbital
Midazolam
Phenobarbital
Ineffective NA NA 1!died
2! recurrent seizures
Savard et al. [29] 1 NA NA NA Ineffective NA NA Died 75d post admission
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Table 2 (Continued )
Reference Number
of Patients
Treated
with MgSO4
MgSO4 dose Mean Duration
of MgSO4
Administration
(days)
Other AED On
Board at Time of
MgSO4
Administration
Electrographic
Seizure Response
Recurrence
after
Withdrawal
of MgSO4
Adverse Effects
to MgSO4
Patient Outcome
Shin et al. [30] 1 NA 1 NA Seizure cessation No NA Good outcome – alert and
conversing
Storchheim
et al. [31]
8 10cc of 25% MgSO4
(up to 3 times)
NA NA/presumed
no other AEDs
8/8 patients receiving
Mg survived their initial
attack, while 0/5 treated
with ‘‘standard of care’’
survived – morphine,
atropine, chloroform
Recurrence in 4/8 NA All 8/8 patients survived their
initial attacks, but ‘‘several’’
patients have had further
attacks after recovering from
the ﬁrst
Strzelczyk
et al. [32]
1 NA 8hr (stopped
due to adverse
effect)
Midalozam
Piracetam
Zonisamide
Clonazepam
Levetiracetam
Valproate
Ineffective N/A 2nd degree
atrioventricular
block
Generalized convlusive RSE
returned
Tan et al. [33] 1 Loading dose=
50mg/kg
Maintenance
dose=20mg/kg/hr
initially, and
changed to
31mg/kg/hr
NA Lorazepam
Phenytoin
Phenobarbitone
Midazolam
Thiopental
Levetiracetam
ketamine
Pyridoxine
Topiramate
Ketogenic diet
Seizure reduction+
cessation
No No cardiovascular or
respiratory effects
Seizure reduction
Val-Morales
et al. [34]
1 Initial = 6g
Load and then
infusion of
54mEq in 24hr
NA Carbamazepine
Phenytoin
Valproate
Midazolam
Propofol
Pyridoxine
No response to MgSO4. N/A NA Never had more seizures.
Deemed a case of pyridoxine
responsive seizure
Visser et al. [35] 2 NA
Goal was serum
Mg level of
3.5mmol/L
5.5 1!midazolam
Clonazepam
Phenytoin
Levetiracetam
Topiramate
2!midazolam
Levetiracetam
1! complete resolution
2! subtle occipital
epileptic discharges
1!no
2!ﬁrst Mg
taper caused
focal convulsions
to return. 2nd
taper led to
seizure reduction
NA 1! complete abolishment of
clinical seizures
2! seizure free for 8months,
with subtle epileptic
discharges on EEG
Madisi et al. [36]* 1 NA NA NA Ineffective NA NA No effect from Mg. RSE was
treated with
PLEX+ rituximab
Madisi et al. [37]* 1 NA NA NA Ineffective NA NA No effect from Mg. RSE was
treated with
PLEX+ rituximab
Sahin et al. [38]** 1 NA Na Pentobarbital
Phenobarbital
Midazolam
Ineffective NA NA Recurring daily seizures on
multiple AEDs
NA, not available data; mg, milligram; kg, kilogram; g, gram; hr, hour; min, minute; d, day; IV, intravenous; PLEX, plasmapheresis; IVIG, intravenous immunoglobulins; RSE, refractory status epilepticus; AED, anti-epileptic drug;
EEG, electroencephalogram.
* Berkley et al. [18], Madisi et al. [36], and Madisi et al. [37] all contain the same patient data. The data from Berkely et al. [18] was the only data included in the ﬁnal analysis.
** Sahin et al. [28,38] report the same patient. The data for this patient was synthesized from both reports, but not duplicated.
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Table 3
Oxford and GRADE Level of Evidence.
Reference Study type Oxford [42]
Level of
Evidence
GRADE
[43–48]
Level of
Evidence
Baxter et al. [17] Retrospective
Case Report
4 D
Berkeley et al. [18] Retrospective
Case Report
4 D
Broomall et al. [19] Retrospective
Case Report
4 D
Dionisio et al. [20] Retrospective
Case Report
4 D
Fisher et al. [21] Retrospective
Case Report
4 D
Gedik et al. [22] Retrospective
Case Report
4 D
Nandakumar
et al. [23]
Retrospective
Case Report
4 D
Neligan et al. [24] Retrospective
Case Report
4 D
Pandey et al. [25] Retrospective
Case Report
4 D
Robakis et al. [26] Retrospective
Case Report
4 D
Sadeh et al. [27] Retrospective
Case Report
4 D
Sahin et al. [28]** Retrospective
Case Report
4 D
Savard et al. [29] Retrospective
Case Report
4 D
Shin et al. [30] Retrospective
Case Report
4 D
Storchheim
et al. [31]
Retrospective
Case Series
4 D
Strzelczyk et al. [32] Retrospective
Case Report
4 D
Tan et al. [33] Retrospective
Case Report
4 D
Val-Morales
et al. [34]
Retrospective
Case Report
4 D
Visser et al. [35] Retrospective
Case Report
4 D
Madisi et al. [36]* Retrospective
Case Report
4 D
Madisi et al. [37]* Retrospective
Case Report
4 D
Sahin et al. [38]** Retrospective
Case Report
4 D
* Berkley et al. [18], Madisi et al. [36], and Madisi et al. [37] all contain the same
patient data. The data from Berkely et al. [18] was the only data included in the ﬁnal
analysis.
** Sahin et al. [28,38] report the same patient. The data for this patient was
synthesized from both reports, but not duplicated.
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However, the exact dosing and duration of IV MgSO4 in the
treatment of non-eclamptic SE/RSE is currently unclear. Second,
the anti-epileptic effect of IV MgSO4 is present even in those cases
with RSE exceeding a month or more in duration. Third, 50% of the
MgSO4 responsive patients had recurrence of seizures upon
withdrawal of the medication. This highlights that IV MgSO4 is
not a permanent solution to seizure control, but provides an
opportunity to titrate other AEDs to effect. It also raises the
question as to the utility of transitioning those patients with
seizure recurrence to an oral MgSO4 regimen. Further study is
clearly warranted. Finally, only a small number of complications
were described, though the cardiac sequelae recorded could
potentially have signiﬁcant consequences for the patient. It is hard
to know if the complications described were entirely related to the
IV MgSO4, or a consequence of multiple drugs and the degree of
their critical illness. Regardless, the side effects of hypermagne-
semia are important to recognize.Our review has signiﬁcant limitations. First, the small number
of studies identiﬁed, all with small patient populations, makes it
difﬁcult to generalize to all non-eclamptic SE/RSE patients. Second,
the retrospective heterogeneous nature of the data makes it
difﬁcult to perform a meaningful meta-analysis. We are thus left
with only descriptive statistics to summarize the available data.
Third, the seizure response to IV MgSO4may not be related entirely
to MgSO4 at all, and perhaps is a reﬂection of the combination of
multiple AEDs working in concert. The exact dosing and sequence
of administration of these AEDs was not clear from the majority of
the reports included within this review. Thus, unfortunately we
cannot make in depth comments on the impact these regimens
may have had on the overall seizure control and response to
MgSO4. Fourth, our comments on the dosing and treatment
regimen for MgSO4 are limited given the small number of studies
and paucity of detail within the articles. Fifth, the potential for
publication bias in the articles reviewed is high. It is likely that
there are many more negative results with IV MgSO4 that have not
made it to the literature. Similarly, we suspect that the
complications of high dose IV MgSO4 therapy in this context are
also under reported. Finally, comments on the impact of IV MgSO4
on outcome in non-eclamptic SE/RSE are limited. Most studies
failed to document outcome and only focused on seizure response.
Currently, the routine use of IV MgSO4 for seizure control in
non-eclamptic SE/RSE cannot be recommended at this time. The
results of this review point to a potential impact that this drug may
have on seizure control. Further prospective study of the utility of
IV MgSO4 in this context is warranted. There exists a need for
international databases that document the impact of therapies in
RSE, as they may shed further light on the impact of IV MgSO4 on
seizure control.
5. Conclusions
Oxford level 4, GRADE D evidence exists to suggest a trend
towards improved seizure control with the use of intravenous
MgSO4 for non-eclamptic RSE. Routine use of IV MgSO4 in non-
eclamptic SE/RSE cannot be recommended at this time. Further
prospective study of this drug is required in order to determine its
efﬁcacy as an anti-epileptic in this setting.
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